fda warning letters glp-1 compounders september 2025 FDA Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

20.37

★★★★☆4.8 (126)

FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing

25.99

★★★★★4.9 (98)

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of compounded GLP-1s, building off increasing pressure to tamp down on the sale of

27.41

★★★★★5.0 (157)

FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers

26.04

★★★★★4.7 (84)

FDA issues 30 warning letters to online GLP-1 compounders

27.03

★★★★★4.9 (203)

Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP-1 compounding while @martymakary is photographed holding bootleg #

27.50

★★★★★5.0 (176)

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

25.16

★★★★★4.8 (132)